Vogl U M, Zehetgruber H, Dominkus M, Hejna M, Zielinski C C, Haitel A, Schmidinger M
Department of Medicine I, Clinical Division of Oncology, University Hospital, Waehringer Guertel 18-20, Vienna A-1090, Austria.
Br J Cancer. 2006 Sep 18;95(6):691-8. doi: 10.1038/sj.bjc.6603327. Epub 2006 Aug 29.
Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy--even incomplete--C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.
转移性肾细胞癌(MRCC)患者的预后和预测因素已从未经治疗的患者或采用几种不同治疗方法的患者中进行了评估。本分析的目的是确定接受低剂量门诊细胞因子联合治疗的患者的预后和预测因素。对99例MRCC患者分析了患者、肿瘤和治疗相关因素之间的关系。这些特征首先在单变量分析中进行检查,然后使用基于Cox回归的逐步建模方法形成多变量模型。核分级、转移灶切除术(即使不完全)、C反应蛋白和乳酸脱氢酶被确定为生存的独立预后因素。分为三个不同风险组的患者有统计学上显著的生存差异(分别为30、22和6个月)。共有43.4%的患者接受了转移灶切除术,大多不完全。风险组归属与治疗反应相关。我们的研究结果强烈建议在对接受免疫治疗或靶向治疗的转移性肾细胞癌患者进行管理时考虑转移灶切除术。